BIIB 8-K Current Reports
BIOGEN INC. - 298 current reports
BIOGEN INC. 8-K Report, Financial Results (Jul 29, 2026)
Biogen Inc. (BIIB) has filed a Form 8-K on July 29, 2026, to announce its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release detailing the company's operational and financial performance during the period. Investors should refer to the furnished press release (Exhibit 99.1) for specific details on revenue, earnings, and other key financial metrics, as well as any forward-looking statements or guidance provided by the company. While the 8-K itself is brief, it signifies the official release of Biogen's quarterly performance data. It's crucial for investors to access and analyze the accompanying press release for a comprehensive understanding of the company's recent financial health, strategic updates, and outlook. The information provided in the press release will be instrumental in evaluating Biogen's current standing and future prospects within the biotechnology sector.
BIOGEN INC. 8-K Report, Financial Results (Jul 1, 2026)
Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026. The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 million pre-tax, translating to an impact of roughly $0.95 per diluted share. Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 million and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.
BIOGEN INC. 8-K/A Report, Exhibit Filing (Jun 10, 2026)
Biogen Inc. (BIIB) has filed an amendment to its previous 8-K filing dated May 14, 2026. The company is clarifying that the previously disclosed acquisition of Apellis Pharmaceuticals, Inc. did not constitute a "significant" acquisition under Regulation S-X. Consequently, Biogen will not be filing the financial statements of Apellis or the pro forma financial information related to the merger as initially anticipated. This amendment is primarily an administrative update to correct the reporting requirements associated with the Apellis acquisition. Investors should note that this filing does not alter the fundamental terms or completion of the acquisition itself, but rather clarifies the regulatory reporting obligations post-transaction. The original disclosures regarding the consummation of the merger remain unchanged.
BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 10, 2026)
Biogen Inc. (BIIB) filed an 8-K on June 10, 2026, reporting the final voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. The meeting's primary outcomes included the election of ten directors to the Board and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, stockholders provided an advisory vote on executive compensation. Investors can view the detailed voting outcomes for each director nominee, which indicate overwhelming support for most candidates, with a few exceptions receiving notably fewer 'for' votes but still comfortably elected. The ratification of the auditor and the advisory vote on executive compensation also received significant stockholder approval, suggesting general confidence in the company's governance and financial oversight for the upcoming fiscal year.
BIOGEN INC. 8-K Report, Material Agreement (May 14, 2026)
Biogen Inc. (BIIB) has filed an 8-K on May 14, 2026, detailing the successful completion of its acquisition of Apellis Pharmaceuticals, Inc. The tender offer for Apellis shares concluded on May 13, 2026, with approximately 82.4% of shares tendered. Following the tender offer, Biogen completed the merger, making Apellis a wholly-owned subsidiary. The acquisition was financed through a combination of cash and $2 billion in term loan facilities secured on May 12, 2026. Key to the transaction are the Contingent Value Rights (CVRs) issued to Apellis shareholders, entitling them to potential future cash payments of up to $4.00 per CVR if specific net sales milestones for SYFOVRE® and related products are met between 2027 and 2031. Additionally, Biogen has entered into a new credit agreement, borrowing $2 billion to fund the acquisition and related expenses, which includes financial covenants such as a maximum consolidated leverage ratio of 3.75 to 1.0.
BIOGEN INC. 8-K Report, Financial Results (Apr 29, 2026)
Biogen Inc. (BIIB) has filed an 8-K report on April 29, 2026, primarily to furnish its first-quarter 2026 earnings press release. This filing indicates that the company is providing an update on its financial performance for the period ending March 31, 2026. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial results and operational highlights announced by the company on the same date. It is important to note that this information is furnished and not deemed "filed" for regulatory purposes, meaning it doesn't carry the same legal implications under Section 18 of the Exchange Act. The core information for investors will be contained within the press release itself, which would typically cover revenue, earnings per share (EPS), operating expenses, and potentially updates on key drug pipelines and commercial performance. Given this is an earnings announcement, the market will be scrutinizing these figures against expectations and prior periods to gauge the company's trajectory and future outlook. Investors should look for any commentary on strategic initiatives, regulatory updates, or significant business developments discussed in the press release.
BIOGEN INC. 8-K Report, Financial Results (Apr 6, 2026)
Biogen Inc. has filed an 8-K report on April 6, 2026, to provide preliminary insights into its first quarter 2026 financial results. The company anticipates recognizing approximately $34 million in pre-tax acquired in-process research and development (R&D), upfront, and milestone expenses. This is expected to negatively impact both GAAP and non-GAAP earnings per diluted share by approximately $0.19 for the quarter. These expenses are typically associated with collaboration and licensing agreements, including upfront and milestone payments, and can also involve premiums on equity securities or asset acquisitions related to in-process R&D. Biogen notes that such expenses are inherently difficult to forecast due to the unpredictable nature of future transactions. Investors should consider this a preliminary disclosure, as final results are subject to financial statement closing procedures and may differ.
BIOGEN INC. 8-K Report, Material Agreement (Mar 31, 2026)
Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger. The proposed transaction involves an upfront cash payment of $41.00 per share of Apellis common stock, plus a contingent value right (CVR) entitling holders to potential future payments of up to $4.00 per share. The CVR payments are tied to specific net sales milestones for SYFOVRE® and related products in future years. This acquisition aims to bolster Biogen's portfolio, particularly in areas where Apellis has established a presence. The deal is structured as a tender offer by Biogen's subsidiary, Aspen Purchaser Sub, Inc., to acquire all outstanding shares of Apellis. This will be followed by a merger under Delaware law, allowing the transaction to be completed without a shareholder vote for Apellis, provided a minimum tender condition is met. The transaction is subject to customary closing conditions, including antitrust approvals. The agreement includes provisions for a termination fee under certain circumstances and has secured support from key Apellis stockholders. Investors should note that the offer has not yet commenced, and further details will be provided in subsequent filings. The transaction is not subject to a financing condition, and Biogen has committed to filing necessary antitrust notifications promptly. This move signifies a significant strategic step for Biogen to expand its therapeutic offerings and market reach.
BIOGEN INC. 8-K Report, Executive Changes (Mar 11, 2026)
Biogen Inc. (BIIB) has announced a key executive change via an 8-K filing dated March 11, 2026. Susan H. Alexander, the Company's Chief Legal Officer, will be departing her role effective at the end of May 2026. This transition marks the end of Ms. Alexander's tenure in a critical leadership position within the organization. The Company has confirmed that a search process is underway to recruit a successor for the Chief Legal Officer position. Investors should monitor the Company's communication for updates on the appointment of a new CLO, as this role is integral to legal and regulatory compliance, strategic decision-making, and risk management. The timing and profile of the incoming CLO could provide insights into Biogen's future strategic direction and governance.
BIOGEN INC. 8-K Report, Executive Changes (Feb 11, 2026)
Biogen Inc. (BIIB) announced a significant leadership transition in its latest 8-K filing. Caroline Dorsa, the current Chair of the Board, will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. The company has clarified that this decision is amicable and not driven by any disputes regarding Biogen's operations, policies, or practices. This change marks the end of Ms. Dorsa's tenure as Chair, a position she has held, and signals a shift in board leadership for the biotechnology firm. In conjunction with this change, the Board has elected Dr. Maria C. Friere to succeed Ms. Dorsa as the Chair of the Board, effective immediately following the Annual Meeting. Dr. Friere's appointment represents a continuation of leadership development within the Board, and investors will be keen to understand her vision and strategic priorities for Biogen. While the filing does not provide details on the specific reasons for Ms. Dorsa's departure beyond her decision not to seek re-election, the smooth transition to Dr. Friere suggests continued stability and a focused approach to governance.
BIOGEN INC. 8-K Report, Financial Results (Feb 6, 2026)
Biogen Inc. (BIIB) has filed a Form 8-K on February 6, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. The core of this filing is the accompanying press release (Exhibit 99.1), which details the company's operational performance and financial condition. Investors should review this press release for specific figures regarding revenue, profitability, and other key financial metrics for the period. While the 8-K itself is a formal notification of the results announcement, the substantive details are contained within the furnished press release. This report serves as an official communication channel for the market to access Biogen's latest financial performance indicators. Investors are advised to consult Exhibit 99.1 for a comprehensive understanding of Biogen's fourth-quarter and year-end 2025 financial outcomes and their potential implications.
BIOGEN INC. 8-K Report, Financial Results (Jan 14, 2026)
Biogen Inc. has filed an 8-K report providing preliminary unaudited estimates for its fourth quarter of 2025 financial results. The company anticipates a significant charge of approximately $222 million on a pre-tax basis related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $1.26. Investors should note that these are preliminary estimates and subject to change as financial closing procedures are completed. The company emphasizes the forward-looking nature of these statements and the inherent risks and uncertainties associated with such projections, urging investors to consult detailed risk factors in their SEC filings.
BIOGEN INC. 8-K Report, Financial Results (Oct 30, 2025)
Biogen Inc. (BIIB) has filed a Form 8-K on October 30, 2025, to report its financial results for the third quarter ended September 30, 2025. The core of this filing is the press release detailing the company's performance during the quarter, which is furnished as Exhibit 99.1. Investors should refer to this press release for specific details on revenue, profitability, and any significant operational updates that impacted the quarter's financial outcomes. While the 8-K itself is a procedural filing to announce these results, the accompanying press release contains the substantive financial and operational information. Investors are encouraged to review the press release for a comprehensive understanding of Biogen's third-quarter performance, including key financial metrics and management's commentary on the business outlook. This information is crucial for assessing the company's current financial health and future prospects.
BIOGEN INC. 8-K Report, Financial Results (Oct 14, 2025)
Biogen Inc. (BIIB) has filed an 8-K report to disclose preliminary financial information for the third quarter of 2025. The company anticipates a pre-tax charge of approximately $2 million related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.01 for the quarter. This specific expense category was introduced in Q1 2025 and encompasses costs from collaboration and license agreements, including upfront and milestone payments, and in some cases, premiums on equity securities and asset acquisitions of acquired in-process R&D. Biogen notes that such expenses are difficult to forecast due to their inherent uncertainty in timing and magnitude. Investors should be aware that these are preliminary estimates and subject to change upon finalization of financial closing procedures.
BIOGEN INC. 8-K Report, Financial Results (Jul 31, 2025)
Biogen Inc. (BIIB) has filed an 8-K report on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any significant operational updates impacting the company's financial condition. This filing is made under Item 2.02, which means the press release is furnished and not deemed 'filed' for certain regulatory purposes. While it provides crucial information for understanding Biogen's recent performance, it's important to note that this disclosure does not alter the company's legal obligations under the Securities Exchange Act of 1934 or the Securities Act of 1933. Investors should consult the press release directly for comprehensive insights into the second quarter's financial outcomes and any forward-looking statements the company may have made.
BIOGEN INC. 8-K Report, Financial Results (Jul 7, 2025)
Biogen Inc. (BIIB) has issued a Current Report on Form 8-K disclosing anticipated financial results for the second quarter of 2025. The company expects to incur approximately $46 million in acquired in-process research and development, upfront, and milestone expenses on a pre-tax basis. This charge is estimated to reduce both GAAP and non-GAAP earnings per diluted share by approximately $0.26 for the quarter.
BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 23, 2025)
Biogen Inc. (BIIB) filed an 8-K on June 23, 2025, reporting the final voting results from its 2025 Annual Meeting of Stockholders held on June 17, 2025. The primary focus of this filing is the outcome of shareholder votes on key corporate governance matters, including the election of directors and the ratification of the independent auditor. The results indicate strong shareholder support for the company's proposed slate of eleven director nominees and the reappointment of PricewaterhouseCoopers LLP as its auditor for the upcoming fiscal year. Additionally, shareholders provided an advisory vote on executive compensation, the results of which are detailed in the filing.
BIOGEN INC. 8-K Report, Corporate Update (May 12, 2025)
Biogen Inc. (BIIB) announced the completion of a significant debt offering, successfully issuing and selling $1.75 billion in aggregate principal amount of senior unsecured notes on May 12, 2025. This offering consists of three tranches: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. The company intends to use the net proceeds from this issuance, along with existing cash, to fully retire its outstanding $1.75 billion of 4.050% Senior Notes due 2025. This strategic refinancing aims to extend Biogen's debt maturity profile and potentially optimize its interest expense.
BIOGEN INC. 8-K Report, Financial Results (May 1, 2025)
Biogen Inc. has filed an 8-K report on May 1, 2025, to announce its financial results for the first quarter ended March 31, 2025. The primary purpose of this filing is to furnish a press release containing these operational and financial highlights. Investors should refer to the press release, attached as Exhibit 99.1, for detailed information regarding the company's performance during the quarter. While the 8-K itself is procedural, the accompanying press release will provide crucial insights into Biogen's revenue generation, profitability, and overall financial health for Q1 2025. Investors will be looking for updates on key product performance, pipeline developments, and any management commentary on future outlook and strategic initiatives. It is important to note that this information is furnished and not deemed 'filed' under Section 18 of the Exchange Act, meaning it does not carry the same legal implications for misstatements as a formally filed document.
BIOGEN INC. 8-K Report, Financial Results (Feb 12, 2025)
Biogen Inc. (BIIB) has filed a Form 8-K on February 12, 2025, to report its financial results for the fourth quarter and full year ended December 31, 2024. The primary purpose of this filing is to provide investors with the company's performance data, which was announced via a press release furnished as Exhibit 99.1. Investors should refer to this press release for specific details on revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook.
BIOGEN INC. 8-K Report, Executive Changes (Jan 15, 2025)
Biogen Inc. has announced a key leadership transition in its finance department, effective March 1, 2025. Sean Godbout has been appointed as the new Vice President, Chief Accounting Officer & Global Corporate Controller, and will also serve as the Company's principal accounting officer. This appointment is part of a broader leadership evolution within the finance team, as Robin Kramer, the current Chief Accounting Officer, transitions to the role of Chief Financial Officer upon the retirement of Michael McDonnell on the same date. Mr. Godbout brings extensive experience to his new role, having been with Biogen since 2007 and most recently serving as Global Corporate Controller. His compensation package includes a base salary of $400,000, eligibility for an annual bonus plan, and long-term incentive grants. The filing also outlines the severance benefits Mr. Godbout is entitled to under the company's executive severance plan for Vice Presidents, which includes provisions for termination without cause and in connection with a corporate change of control. Investors should note this as a routine but important update regarding financial leadership continuity.
BIOGEN INC. 8-K Report, Financial Results (Oct 30, 2024)
Biogen Inc. (BIIB) has filed a Form 8-K on October 30, 2024, to report its financial results for the third quarter ended September 30, 2024. The primary purpose of this filing is to furnish the press release announcing these results, which provides key operational and financial information to investors. While this filing itself doesn't contain detailed financial statements, it directs investors to the attached press release for the comprehensive quarterly update. Investors should focus on the press release (Exhibit 99.1) for specific details regarding revenue, earnings per share, operating expenses, and any forward-looking guidance. This report serves as the official notification of the release of Biogen's Q3 2024 performance data, allowing the market to assess the company's ongoing business trends and strategic execution.
BIOGEN INC. 8-K Report, Executive Changes (Oct 30, 2024)
Biogen Inc. (BIIB) announced a planned leadership transition in its finance department via an 8-K filing dated October 30, 2024. Chief Financial Officer Michael McDonnell will retire effective February 28, 2025, after a distinguished tenure. To ensure a seamless handover, Mr. McDonnell will work closely with his successor, Robin Kramer, who has been appointed as the new Chief Financial Officer. Ms. Kramer's appointment will be effective upon Mr. McDonnell's retirement, signaling a new chapter for Biogen's financial leadership.
BIOGEN INC. 8-K Report, Executive Changes (Sep 12, 2024)
Biogen Inc. announced an expansion of its Board of Directors with the appointment of two new independent directors, Dr. Lloyd Minor and Professor Sir Menelas Pangalos. Dr. Minor's appointment is effective October 1, 2024, while Professor Sir Pangalos will join on January 1, 2025. Both are expected to serve until the company's 2025 Annual Meeting of Stockholders. These appointments bring significant expertise to Biogen's board, with Dr. Minor being a prominent figure in academic medicine and university leadership, and Professor Sir Pangalos having extensive experience in neuroscience research and development within the pharmaceutical industry. Investors should view these additions as a positive step towards strengthening the board's strategic oversight and scientific acumen, potentially enhancing the company's innovation and long-term growth prospects.
BIOGEN INC. 8-K Report, Material Agreement (Aug 14, 2024)
Biogen Inc. (BIIB) announced on August 14, 2024, through an 8-K filing, the entry into a new $1.5 billion, five-year unsecured, revolving credit facility with Bank of America, N.A. This new facility replaces the Company's previous credit agreement. As of the closing date, no funds had been drawn under this new facility, indicating Biogen maintains a strong liquidity position. The new credit agreement provides Biogen with significant financial flexibility for general corporate purposes. The interest rates are variable, tied to benchmark rates like SOFR, EURIBOR, etc., plus an applicable margin that depends on the Company's debt ratings. The facility includes sub-limits for letters of credit and swing line loans. Importantly, the agreement includes a financial covenant requiring Biogen to maintain a consolidated leverage ratio of no more than 3.75 to 1.0, with a temporary increase allowed to 4.25 to 1.0 in case of material acquisitions.
BIOGEN INC. 8-K Report, Financial Results (Aug 1, 2024)
Biogen Inc. (BIIB) has filed an 8-K on August 1, 2024, to report its financial results for the second quarter ended June 30, 2024. The core of this filing is the press release, furnished as Exhibit 99.1, which details the company's operational performance and financial condition. Investors should refer to this press release for the specific quantitative and qualitative information regarding the quarter's results. While the 8-K itself is a formal filing, it directs stakeholders to the accompanying press release for the critical financial data. This is a standard procedure for earnings announcements, meaning the detailed performance metrics, revenue figures, profitability, and any forward-looking statements are contained within the furnished press release, which is incorporated by reference into this filing.
BIOGEN INC. 8-K Report, Bylaw Amendment (Jun 25, 2024)
Biogen Inc. filed an 8-K on June 25, 2024, detailing the outcomes of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The most significant event from an investor perspective was the approval of an amendment to the Company's Certificate of Incorporation to allow for the exculpation of certain company officers, to the extent permitted by Delaware law. This change, which was previously approved by the Board of Directors, aims to provide a layer of protection for officers against certain liabilities. Additionally, the filing provides the final voting results for all proposals presented at the meeting. These included the election of nine directors to the Board, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024, an advisory vote on executive compensation, and the approval of two equity incentive plans: the 2024 Omnibus Equity Plan and the 2024 Employee Stock Purchase Plan. All proposals received substantial support from stockholders, indicating general alignment with management's decisions and governance.
BIOGEN INC. 8-K Report, Financial Results (Apr 24, 2024)
Biogen Inc. (BIIB) filed an 8-K on April 24, 2024, to report its financial results for the first quarter ended March 31, 2024. The core of this filing is the press release attached as Exhibit 99.1, which contains the company's operational and financial performance for the period. Investors should refer to this press release for detailed information regarding Biogen's Q1 2024 earnings, including revenue, profitability, and any forward-looking guidance provided. This 8-K serves as a notification of the release of these results and incorporates the press release by reference. While the 8-K itself is a formal SEC filing, the substantive financial details and commentary are contained within the accompanying press release. Investors and analysts will be reviewing these figures closely to assess the company's performance against expectations and to understand the strategic direction and outlook for Biogen in the coming quarters, particularly concerning its key therapeutic areas and product portfolio.
BIOGEN INC. 8-K Report, Financial Results (Feb 13, 2024)
Biogen Inc. announced its fourth quarter and full-year 2023 financial results on February 13, 2024, via a press release filed as an 8-K. While the filing itself primarily serves to incorporate the press release, the key information for investors lies within the reported financial performance and operational updates. Investors should review the furnished press release for detailed figures on revenue, profitability, and any forward-looking guidance provided by the company. The press release will offer insights into the company's performance drivers, such as sales of key products and any progress or setbacks in its drug pipeline, which are crucial for understanding Biogen's current financial health and future prospects.
BIOGEN INC. 8-K Report, Bylaw Amendment (Dec 12, 2023)
Biogen Inc. (BIIB) filed an 8-K on December 12, 2023, detailing amendments to its Fifth Amended and Restated Bylaws, effective December 6, 2023. The primary focus of these amendments is to update procedural mechanics and disclosure requirements related to stockholder meetings, particularly concerning the submission of business proposals and director nominations. These changes aim to enhance transparency and streamline the proxy solicitation process. Key updates include more stringent disclosure requirements for stockholders proposing business, such as detailing derivative or synthetic arrangements that mirror long positions in company shares. Additionally, provisions related to director nominations have been enhanced to align with Rule 14a-19 of the Securities Exchange Act, requiring significant proxy solicitation efforts (at least 67% of voting power) and specific disclosures from nominating stockholders and their nominees. The amendments also clarify procedures for meeting adjournments, quorum establishment, and the revocability of proxies.
BIOGEN INC. 8-K Report, Executive Changes (Nov 8, 2023)
Biogen Inc. announced a key addition to its Board of Directors, effective January 1, 2024. Monish Patolawala has been elected as a new director, filling a vacancy and serving until the 2024 Annual Meeting. Mr. Patolawala's expertise is particularly noteworthy as he qualifies as an "audit committee financial expert," a designation important for oversight of financial reporting and internal controls. This appointment suggests a continued focus on robust financial governance and potentially strengthens the composition of the Board's Audit Committee, should he be appointed to it.
BIOGEN INC. 8-K Report, Financial Results (Nov 8, 2023)
Biogen Inc. (BIIB) filed an 8-K on November 8, 2023, primarily to furnish its press release announcing third-quarter 2023 results. While the filing itself contains minimal new information beyond the announcement of the press release, investors should refer to the furnished press release (Exhibit 99.1) for detailed financial and operational performance updates. This filing serves as the official notification of the release of these results.
BIOGEN INC. 8-K/A Report, Shareholder Vote Results (Sep 28, 2023)
This amendment to Biogen Inc.'s (BIIB) 8-K filing provides an update on the outcome of an advisory vote concerning the "Say-on-Frequency" proposal presented at its Annual Meeting. The company's stockholders expressed a preference for the "Say-on-Pay" advisory vote to be conducted annually. Consequently, Biogen's Board of Directors has determined that future "Say-on-Pay" votes will indeed be held every year.
BIOGEN INC. 8-K Report, Corporate Update (Sep 26, 2023)
Biogen Inc. has announced the successful completion of its acquisition of Reata Pharmaceuticals, Inc. on September 26, 2023. This significant event marks a strategic move for Biogen, aiming to enhance its portfolio and future growth prospects through the integration of Reata's assets and pipeline. Investors should note that this acquisition is expected to impact Biogen's commercial business, R&D pipeline, and overall financial and operating results, as detailed in the company's forward-looking statements. The press release accompanying this filing contains extensive forward-looking statements regarding the potential benefits and expected outcomes of this transaction, as well as Biogen's broader strategic initiatives like the 'Fit for Growth' program. While the company expresses optimism about the future, it also acknowledges the inherent risks and uncertainties associated with drug development, commercialization, and the integration of acquired businesses. Investors are advised to review Biogen's SEC filings for a comprehensive understanding of these risks.
BIOGEN INC. 8-K Report, Material Agreement (Sep 1, 2023)
Biogen Inc. (BIIB) announced on September 1, 2023, its entry into a new $1.5 billion unsecured credit facility with JPMorgan Chase Bank, N.A., effective August 28, 2023. This facility is designed to fund a significant portion of the consideration for Biogen's previously announced acquisition of Reata Pharmaceuticals, Inc., as well as repay certain Reata indebtedness and related expenses. The credit facility is comprised of two tranches: a $750 million 364-day tranche (Tranche A) and a $750 million three-year tranche (Tranche B). The new credit facility replaces a previously announced bridge loan facility. The interest rates on borrowings will be tied to either Term SOFR or a Base Rate, plus an applicable margin based on Biogen's debt ratings. The agreement includes customary covenants and events of default, as well as a financial covenant requiring Biogen to maintain a maximum consolidated leverage ratio of 3.5 to 1.0, which can temporarily increase to 4.0 to 1.0 under specific circumstances related to the Reata acquisition and other material acquisitions.
BIOGEN INC. 8-K Report, Material Agreement (Jul 31, 2023)
Biogen Inc. (BIIB) has announced a material definitive agreement to acquire Reata Pharmaceuticals, Inc. through a merger. This strategic move involves Biogen acquiring all outstanding shares of Reata's common stock for a cash consideration of $172.50 per share, valuing the transaction at a significant amount. The merger agreement has been unanimously approved by the boards of directors of both companies, indicating strong support for the transaction. This acquisition is expected to be financed through a combination of Biogen's existing cash reserves and a new $1.5 billion bridge loan facility, demonstrating Biogen's financial capacity to complete the deal. The transaction is subject to customary closing conditions, including Reata stockholder approval and regulatory clearances. This acquisition represents a significant step in Biogen's growth strategy, likely aimed at expanding its therapeutic portfolio and market presence. Investors should monitor the progress of Reata's stockholder approval process and any regulatory reviews. The definitive agreement includes customary provisions such as representations, warranties, and covenants, along with 'no-shop' clauses to prevent Reata from soliciting competing offers, though exceptions exist for superior proposals. The 'Fit for Growth' program mentioned in the cautionary notes suggests ongoing efforts by Biogen to optimize its operations and financial structure alongside strategic acquisitions.
BIOGEN INC. 8-K Report, Corporate Update (Jul 28, 2023)
Biogen Inc. (BIIB) announced a significant strategic move through an 8-K filing on July 28, 2023, detailing its entry into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (Reata). This transaction, structured as a merger where Reata will become a wholly-owned subsidiary of Biogen, represents a substantial investment aimed at bolstering Biogen's pipeline and commercial offerings. The announcement was accompanied by a joint press release and an investor webcast presentation, which are attached as exhibits to the filing. This acquisition signals Biogen's commitment to growth and expansion, likely focusing on Reata's therapeutic areas which may complement Biogen's existing portfolio. Investors should closely monitor the progress of this merger, including the satisfaction of closing conditions and regulatory approvals, as it could materially impact Biogen's future financial performance, strategic direction, and market position. The cautionary note included highlights the inherent risks and uncertainties associated with drug development, commercialization, and significant corporate transactions like this proposed merger.
BIOGEN INC. 8-K Report, Financial Results (Jul 25, 2023)
Biogen Inc. (BIIB) filed an 8-K on July 25, 2023, to report its financial results for the second quarter ended June 30, 2023. The core of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance during the quarter. Investors should review this press release for comprehensive updates on operational and financial conditions. While the 8-K itself does not contain the detailed financial data, it serves as the official notification that Biogen has publicly disclosed its Q2 2023 earnings. The press release, incorporated by reference, is the primary source for understanding revenue, profitability, product performance, and any forward-looking statements or strategic updates provided by the company. It's important to note that the information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, meaning it doesn't carry the same liability as formally filed documents under Section 18 of the Exchange Act.
BIOGEN INC. 8-K Report, Shareholder Vote Results (Jun 29, 2023)
Biogen Inc. (BIIB) filed an 8-K on June 29, 2023, detailing the results of its 2023 Annual Meeting of Stockholders held on June 26, 2023. The meeting primarily focused on routine corporate governance matters, including the election of directors and the ratification of the independent auditor. All proposed items received strong support from stockholders, indicating continued confidence in the company's leadership and oversight. Key outcomes include the re-election of seven incumbent directors and the election of a new director, Susan K. Langer, to the Board. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the upcoming fiscal year. Additionally, stockholders provided advisory approval for executive compensation and supported an annual frequency for such advisory votes. The overwhelming support for these proposals suggests a generally favorable view of Biogen's current governance structure and practices among its shareholders.
BIOGEN INC. 8-K Report, Corporate Update (May 3, 2023)
Biogen Inc. (BIIB) announced on May 3, 2023, that the European Commission has made a decision regarding the regulatory market protection period for its drug Tecfidera. The decision extends this protection until February 2, 2025. This extension is significant for investors as it provides continued exclusivity for Tecfidera in the European market, potentially safeguarding its revenue stream from direct competition for a longer period than previously anticipated. This regulatory development is a positive signal for Biogen, reinforcing the commercial value of Tecfidera and providing a clearer visibility into its future revenue generation in a key geographic region. Investors will want to monitor any implications this might have on Tecfidera's sales performance and Biogen's overall financial outlook during this extended protection period.
BIOGEN INC. 8-K Report, Financial Results (Apr 25, 2023)
Biogen Inc. (BIIB) filed an 8-K on April 25, 2023, primarily to report its first-quarter 2023 financial results and operational updates. The company issued a press release on the same day, which is furnished as part of this filing. Investors should refer to this press release for detailed financial performance metrics, including revenue, earnings, and any forward-looking guidance provided by the company for the upcoming periods. This filing serves as the official channel for disseminating these critical quarterly updates.
BIOGEN INC. 8-K Report, Bylaw Amendment (Apr 18, 2023)
Biogen Inc. (BIIB) filed an 8-K on April 18, 2023, primarily to announce an amendment to its corporate governance documents. The Board of Directors approved changes to the company's Fourth Amended and Restated Bylaws, effective April 12, 2023. The most significant change is the renaming of the "Chairman" title to "Chair." This amendment is largely administrative and aims to align Biogen's internal governance with contemporary corporate terminology, promoting gender neutrality in leadership titles. Investors should note that this filing does not contain any material financial updates, strategic shifts, or significant operational news. The key takeaway is a procedural update to Biogen's bylaws regarding leadership titles.
BIOGEN INC. 8-K Report, Executive Changes (Mar 9, 2023)
Biogen Inc. (BIIB) announced a significant leadership change in its Board of Directors through an 8-K filing on March 9, 2023. Stelios Papadopoulos, the current Chair of the Board, has decided not to stand for re-election at the upcoming 2023 Annual Meeting of Stockholders. Importantly, the company clarified that Dr. Papadopoulos' decision is not due to any disagreements regarding Biogen's operations, policies, or practices, which suggests a smooth transition rather than a response to internal conflict. Concurrently, Biogen's Board has elected Caroline D. Dorsa to succeed Dr. Papadopoulos as Chair of the Board, with her term commencing after the Annual Meeting. This appointment signifies a planned succession for the leadership of the Board, providing continuity and a new direction. Investors should monitor the impact of this leadership transition on the company's strategic direction and governance moving forward.
BIOGEN INC. 8-K Report, Financial Results (Feb 15, 2023)
Biogen Inc. (BIIB) has filed a Form 8-K on February 15, 2023, to report its financial results for the fourth quarter and full year ended December 31, 2022. This filing primarily consists of a press release (Exhibit 99.1) containing the company's operational and financial performance details for the specified periods. Investors should refer to this press release for the specific financial figures, including revenue, earnings per share, and any forward-looking guidance provided by the company. This 8-K serves as the official notification and aggregation point for this important financial data.
BIOGEN INC. 8-K Report, Executive Changes (Nov 10, 2022)
Biogen Inc. announced a significant leadership change with the appointment of Christopher A. Viehbacher as its new President and Chief Executive Officer (CEO), effective November 14, 2022. Mr. Viehbacher brings extensive experience, including serving as Global CEO of Sanofi and co-founding Gurnet Point Capital. He will succeed Michel Vounatsos, who will step down as CEO and resign from the Board, remaining as an employee for a transitional period. This change in leadership marks a pivotal moment for Biogen as it navigates its future strategy and growth initiatives.
BIOGEN INC. 8-K Report, Financial Results (Oct 25, 2022)
Biogen Inc. filed an 8-K on October 25, 2022, to report its financial results for the third quarter ended September 30, 2022. The primary purpose of this filing is to furnish the press release announcing these results, which provides investors with key performance metrics and financial condition updates. Investors should review the press release for details on revenue, profitability, and any significant business developments during the quarter.
BIOGEN INC. 8-K/A Report, Financial Results (Jul 20, 2022)
Biogen Inc. (BIIB) filed a Form 8-K/A on July 20, 2022, primarily to correct a minor typographical error in the header dates of a previously issued press release concerning its second-quarter 2022 results. The original press release announced Biogen's operational and financial performance for the quarter ended June 30, 2022. Investors should note that this filing is an amendment to correct a date error and does not introduce new financial results or strategic information beyond what was in the original press release. The corrected press release has been re-furnished as Exhibit 99.1. It's important for investors to understand that this specific document (the 8-K/A) is purely for a date correction and the substantive financial details would be found in the original press release it references. The filing clarifies that the revised press release is furnished, not filed, meaning it does not carry the same legal implications under certain sections of the Securities Exchange Act of 1934.
BIOGEN INC. 8-K Report, Financial Results (Jul 20, 2022)
Biogen Inc. (BIIB) filed an 8-K on July 20, 2022, primarily to report its financial results for the second quarter ended June 30, 2022, via an attached press release. This filing serves as the primary vehicle for investors to access the company's latest operational and financial performance. While the 8-K itself is brief, the furnished press release (Exhibit 99.1) contains the detailed financial data and commentary crucial for evaluating Biogen's current standing and future outlook. Investors should refer to the press release for specific figures related to revenue, earnings per share, and any relevant business updates or strategic developments announced during the quarter. It's important to note that the information provided is furnished and not deemed 'filed,' which has implications under SEC regulations. The key takeaway for investors is to access and review the press release to understand the Q2 2022 performance of Biogen.
BIOGEN INC. 8-K Report, Executive Changes (Jun 21, 2022)
Biogen Inc. (BIIB) filed an 8-K on June 21, 2022, primarily reporting the departure of Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization, effective June 30, 2022. This departure marks a change in key leadership within the company's commercial and strategic operations. The filing also provides the final voting results from Biogen's 2022 Annual Meeting of Stockholders held on June 15, 2022. Key outcomes include the election of eleven nominees to the Board of Directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2022, and the advisory vote on executive compensation. While the election of directors and auditor ratification passed with strong support, the advisory vote on executive compensation received a split decision, indicating potential investor concerns regarding compensation packages.
BIOGEN INC. 8-K Report, Financial Results (May 3, 2022)
Biogen Inc. (BIIB) filed an 8-K on May 3, 2022, primarily announcing its first-quarter 2022 financial results via a press release, which is furnished as an exhibit. While the specific financial details are within the press release (Exhibit 99.1), this filing highlights a significant leadership transition. The company has initiated a search for a new Chief Executive Officer (CEO). In the interim, Michel Vounatsos will continue to serve as CEO, maintaining his current compensation and benefits, with pro-rated equity vesting for his tenure during this period. Mr. Vounatsos will also remain on the Board of Directors until he departs as CEO. This leadership change is a key development for investors to monitor, alongside the company's ongoing financial performance.